Small cell lung cancer · line 2 · Lurbinectedin monotherapy (SCLC, relapsed/refractory, ≥2L)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-LURBINECTEDIN-SCLC-RR |
| ID | IND-SCLC-RR-LURBINECTEDIN |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | DIS-SCLC |
| Sources | SRC-ESMO-SCLC-2021 SRC-NCCN-SCLC-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L for R/R SCLC after platinum-based 1L. No biomarker dependency (lurbinectedin is non-targeted DNA-damage agent); applicability driven by line-of-therapy + CTFI + organ function. Ukraine access constraint dominant (not registered, not NSZU; out-of-pocket USD 8-12K/cycle). Algorithm wiring deferred — SCLC R/R algorithm not yet authored in KB; out of chunk scope. Trial sources SRC-ATLANTIS-PAZ-ARES-2023 + SRC-TRIGO-2020 pending KB ingestion.
Used By
Algorithms
ALGO-SCLC-2L- ALGO-SCLC-2L
Indication
IND-SCLC-PLATINUM-RECHALLENGE- IND-SCLC-PLATINUM-RECHALLENGE